US FDA says shortage of dialysis device component to extend through early fall

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

US FDA says shortage of dialysis device component to extend through early fall

, Reuters - 5:23 PM ET 3/14/2025 Company News

March 14 (Reuters) - The U.S. Food and Drug Administration said on Friday that supply interruptions of hemodialysis bloodlines, a key component in dialysis devices, are expected to continue through early fall 2025 due to recent supplier issues.

Hemodialysis bloodlines are sets of tubes that connect a patient's bloodstream to the dialysis device during treatment.

The health agency's statement follows a January announcement from medical device maker B. Braun, which cited supply and labor constraints disrupting production of some hemodialysis bloodlines, with inventory expected to run out by January 20.

The FDA recommended health care providers conserve the use of the bloodlines when possible, adding that it is monitoring the situation and is working with manufacturers and dialysis providers to mitigate impact on patients.

(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)

(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.